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Sirolimus Conversion Efficacy for Graft Function Improvement 
and Histopathology in Renal Recipients with Mild to Moderate 
Renal Insufficiency
This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves 
renal function and histopathology in calcineurin inhibitor (CNI)-treated renal recipients 
with mild to moderate renal insufficiency. SRL conversion from CNI was performed in 
patients who underwent kidney transplantation from 6 months to 5 yr prior to screening. 
Forty-five patients were enrolled. The effect of SRL conversion on graft function was 
evaluated, and protocol biopsies were performed preconversion and 1 yr after conversion. 
Overall graft function after SRL conversion gradually improved, and the improvement in 
renal function was closely associated with the shorter duration of CNI exposure. When we 
divided the patients by the duration of CNI exposure, the patients with less than 1 yr of 
CNI exposure demonstrated significant improvement, but patients with a greater than 1 yr 
CNI exposure did not exhibit significant improvement. In contrast, protocol biopsies 
demonstrated no significant improvements in the modified “ah” score or other Banff scores 
after SRL conversion. Furthermore, the duration of CNI treatment prior to SRL conversion 
was not associated with histological findings 1 yr after SRL conversion. SRL conversion 
improved graft function in renal recipients with mild to moderate renal insufficiency, but 
this effect is not accompanied by histological improvement.
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INTRODUCTION
Calcineurin inhibitors (CNI) are widely used immunosuppressants that greatly de-
crease the incidence of acute rejection and improve both graft and patient survival 
rates in kidney transplantation patients. However, the long-term use of CNI produces 
chronic allograft dysfunction due to nephrotoxicity (1, 2). Progressive chronic nephro-
toxicity is a major long-term toxic effect of CNI, and it is associated with mild-to-mod-
erate renal dysfunction (1-3).
 Sirolimus (SRL) is an effective immunosuppressive agent that improves long-term 
graft function and survival without nephrotoxicity (4, 5). SRL has been used for prima-
ry immunosuppression without CNI, early withdrawal or the minimization of CNI, and 
early or late conversion from CNI (4, 6-10). Some clinicians advocate the early use of 
SRL and CNI withdrawal because SRL has many beneficial effects, such as the reduc-
tion of malignancy risk after renal transplantation and improved long-term outcomes 
and associated cardiovascular risk profiles (11-13). However, the early use of SRL may 
increase the incidence of postoperative issues, such as impaired wound healing or 
lymphocele, and it may extend the duration of delayed graft function (14-17).
 The most efficacious regimen for long-term graft survival is not known. Additionally, 
no evidence of an SRL reversal of renal function or histology of renal grafts with impair-
ed renal function has been published. The current study investigated the impact of SRL 
conversion therapy from CNI on graft function and histology after CNI exposure for a 
certain period.
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MATERIALS AND METHODS
Study design
This study was a 12-month, prospective, nonrandomized, two-
center, open-label, noncomparative study that included a screen-
ing period, conversion of immunosuppressive agent, and a treat-
ment period. 
 The current study was designed for patients who underwent 
kidney transplantation from 6 months to 5 yr prior to the screen-
ing point. CNI was gradually reduced by 25% of the initial dose 
each week enrollbeginning from the first administration of SRL 
(Rapamune®, Pfizer, Philadelphia, PA, USA). A loading dose of 
SRL was administered on the first day of conversion. The load-
ing dose of SRL was determined based on the previous use of 
mycophenolate mofetil (MMF) or mycophenolic acid (MPA). 
MMF or MPA patients received a loading dose of 6 mg/day SRL 
on the first day and a maintenance dose of 2 mg/day SRL, which 
was adjusted to target trough levels of 7-15 ng/mL. Non-MMF 
or MPA patients received an SRL loading dose of 8 mg/day on 
the first day and a maintenance dose of 4 mg/day SRL, which 
was adjusted to target trough levels of 10-18 ng/mL. Prednisone 
or an equivalent dose of deflazacort was maintained with the 
preconversion dosage (5-10 mg/day). Mandatory protocol bi-
opsies were performed during the preconversion period and 1 
yr after conversion (Fig. 1). 
Objectives
This study evaluated whether SRL conversion therapy from CNI 
improved renal function in renal recipients with mild to moder-
ate graft insufficiency. The secondary objective evaluated wheth-
er SRL conversion therapy improved histological results 12 mon-
ths after conversion.
 
Inclusion/exclusion criteria
Kidney transplant recipients who were over 18 yr of age and 
who received CNI for at least 3 months before screening were 
included in the current study. To define mild to moderate renal 
insufficiency, we made the inclusion criteria according to renal 
function including estimated glomerular filtration and protein-
uria. The inclusion criteria had a lower limit of estimated glo-
merular filtration rate of over 40 mL/min (eGFR) as measured 
by the Cockcroft-Gault formula at screening and an upper limit 
of proteinuria of 300 mg/day using a 24-hr urine collection to 
exclude grafts with irreversible damage. Twenty four hour urine 
collection was performed only for the patients who showed 
eGFR over 40 mL/min to skip unnecessary evaluation. 
Patients who underwent kidney transplantation 6 months to 5 
yr prior to screening were enrolled. Exclusion criteria included 
combined organ transplantation with other organs, an acute 
rejection episode within 3 months, generalized or localized in-
fection, abnormal chest radiographic findings, unstable angina 
or arrhythmia, malignancy within 5 yr or post-transplant lym-
phoproliferative disease (PTLD), and the administration of drugs 
with pharmacokinetic effects on SRL, such as terfenadine, cis-
apride, astemizole, pimozide, ketoconazole, voriconazole, and 
fluconazole. Additionally, patients with an allergic reaction his-
tory with SRL, hepatitis B or C, HIV positivity, pregnancy, breast 
feeding, or a major operation history within 4 weeks were ex-
cluded. Patients with leucopenia ( ≤ 3,000/μL), thrombocyto-
penia (≤ 100,000/μL), hypertriglyceridemia (≥ 400 mg/dL, fast-
ing), hypercholesterolemia (≥ 300 mg/dL, fasting), or other ab-
normal lipid profiles (fasting HDL-c ≤ 30 mg/dL, or fasting 
LDL-c ≥ 200 mg/dL) at screening were additionally excluded. 
The patients were divided into three groups according to the 
duration of CNI exposure: 1) 6 months-1 yr, 2) 1-3 yr, and 3) 3-5 
yr. The changes in renal function and histological findings were 
evaluated in each group. 
Safety, tolerability and efficacy
The safety of the immunosuppressive protocol was assessed by 
monitoring the frequency, severity, duration and relation with 
the study drug of adverse events throughout the study period, 
including episodes of serious infection, immunosuppression-
related complications and deviations from the study protocol 
for any reason. Laboratory tests, including hematology, bioche-
mistry and urinalysis, were performed at preconversion and 0, 
2, 4, 8, 12, 20, 28, 36, 44, and 52 weeks after conversion. Protocol 
biopsies were performed at the screening point and 1 yr after 
conversion. Proteinuria and creatinine clearance (CCr) were 
measured using 24-hr urine collection at preconversion and 4, 
12, 28, and 52 weeks after conversion. 
Histological evaluation
All biopsy slides from the two centers were collected and review-
ed by one pathologist who specialized in transplant kidney pa-
thology. Histological changes in glomerula, tubules, intersti-
tium and blood vessels were graded using the Banff 97 classifi-
cation with the 2005 modifications (18, 19). Additionally, CNI 
toxicity was graded according to the modified Banff classifica-
Screening               0         1 week  2 weeks  3 weeks  4 weeks                                                          1 yr
Sirolimus loading and maintain (trough level: 7-15 ng/mL)
CNI
(6 mg/d)  (2 mg/d)*
MMF or MPA (continue)
Biopsy
Start of 
Conversion
Biopsy
tapering
Fig. 1. Study design. After screening, calcineurin inhibitors were converted into siroli-
mus for a 4-week overlapped period (CNI dose was reduced by 25% each week). 
*Non-MMF and MPA patients received a loading dose of 8 mg/day and a mainte-
nance dose of 4 mg/day. MMF, mycophenolate mofetil; MPA, mycophenolic acid; CNI, 
calcineurin inhibitor.
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tion (“ah” score) suggested by Sis et al. (20). This modified “ah” 
scoring system is based on the number and shape of arterial 
hyalinization and graded as follows: score 0 = no typical lesions 
of CNI arteriolopathy, score 1 = replacement of degenerated 
smooth muscle cells by hyaline deposits in only one arteriole 
but no circular involvement, score 2 = replacement of dege-
nerated smooth muscle cells by hyaline deposits in more than 
one arteriole but no circular involvement, and score 3 = replace-
ment of degenerated smooth muscle cells by hyaline deposits 
with circular involvement and independent of the number of 
arterioles involved.
Statistical analysis
Continuous data were reported as the means ± SD and com-
pared using the two-sided Student’s t-test or ANOVA. Compari-
sons between the groups for categorical variables were analyzed 
using the chi-square test and the Fischer’s exact test. Serial lab-
oratory findings were compared using the Wilcoxon method 
for nonparametric tests or a paired t-test. Statistical analysis was 
performed using SPSS for Windows (version 14.0; SPSS, Chica-
go, IL, USA). P values less than 0.05 were regarded as significant.
Ethics statement
Written informed consents for participation in this study were 
obtained from all patients before participating in this clinical 
trial. Severance Hospital IRB (4-2006-0241), Seoul St. Mary’s 
Hospital IRB (KCMC06MI158) and Korean FDA (Clinical Trials 
Management Division-344) approved this protocol.
RESULTS
Study population and patient demographics
The screening was conducted between March 2007 and Decem-
ber 2009. A total of 46 patients who underwent kidney trans-
plantation 6 months to 5 yr prior to the screening time point, 
were screened. There were 39 living donor and 7 deceased do-
nor kidney transplantations. One screening failure occurred 
due to a low eGFR under 40 mL/min. Forty-five patients were 
enrolled in the current study, and preconversion biopsies were 
performed in all enrolled patients. CNI was completely con-
verted to SRL 4 weeks after loading SRL. Four patients dropped 
out during the 52-week study period because of one case of 
acute pancreatitis, one case of severe edema, and two cases of 
pneumonitis. Thirty-seven protocol biopsies (postconversion 
biopsy) were completed after the 52-week study period (Fig. 2). 
 The mean age of enrolled patients was 37.1 ± 10.9 yr. Thirty-
eight male patients and 7 female patients were included. Twen-
ty-eight patients received tacrolimus (62.2%), and 17 patients 
received cyclosporine (37.8%) prior to SRL conversion. The mean 
duration of CNI exposure after kidney transplantation was 28.6 
± 16.8 months. Forty-three patients had used MMF or MPA, but 
two patients maintained their immunosuppression without 
antimetabolites. Ten of the 37 patients who completed the two 
protocol biopsies were exposed to CNI for 6 months to 1 yr, 16 
patients for 1-3 yr and 11 patients for 3-5 yr after transplantation. 
No significant differences in preconversion clinical characteris-
tics, such as sex, age, HLA mismatch, donor type, immunosup-
pressive agents, eGFR, proteinuria, and serum cholesterol level, 
Table 1. Demographics
Variables
Histological findings
Duration of CNI exposure
P value
6 month-1 yr (n = 10) 1-3 yr (n = 16) 3-5 yr (n = 11)
Age (yr) 35.0 ± 11.4 38.3 ± 11.5 37.2 ± 8.5 0.745
Sex (Male vs. Female) 10:0 12:4 10:1 0.243
Donor type (Living vs. Deceased) 10:0 11:5 10:1 0.115
HLA mismatch 3.1 ± 1.7 2.6 ± 0.9 2.9 ± 1.2 0.563
Major immunosupressive agent (CsA vs. Tacrolimus) 3:7 3:13 7:4 0.060
Mean CCr at screening (mL/min/1.73 m2) 56.1 ± 15.1 58.5 ± 9.7 61.1 ± 8.4 0.689
Proteinuria at screening (mg/24 hr) 108.8 ± 49.4 90.6 ± 35.8 112.5 ± 69.2 0.496
Mean eGFR* at screening 56.2 ± 15.1 58.4 ± 12.1 58.1 ± 9.7 0.904
Serum cholesterol at screening point 171.2 ± 32.6 190.2 ± 42.0 184.6 ± 37.6 0.475
*eGFR estimated by Cockcroft-Gault. CNI, calcineurin inhibitor; CsA, cyclosporine A; CCr, creatinine clearance; eGFR, estimated glomerular filtration rate.
Fig. 2. Study population. Forty-six patients were screened, and 45 preconversion bi-
opsies were performed. After the 52-week study period, 37 post-conversion biopsies 
were completed.
Patient screening (n = 46)
Screening failure (n = 1)
Drop out (n = 4)
Protocol biopsy not done (n = 4)
Acute pancreatitis (n = 1)
Edema (n = 1)
Pneumonitis (n = 2)
Patient enrollment (n = 45)
Preconversion graft biopsy
Follow up for 52 weeks (n = 41)
Study completed (n = 37)
CNI → SRL for 4 weeks
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were observed according to CNI exposure duration (Table 1). 
Renal function
Serum creatinine at the screening point was 1.62 ± 0.29 mg/dL, 
and it gradually decreased to 1.49 ± 0.27 mg/dL 52 weeks later 
(P < 0.001). CCr at preconversion was 57.28 ± 10.93 mL/min/ 
1.73 m2. CCr was mildly increased at 4, 12, 28, and 52 weeks af-
ter conversion. The CCr value 52 weeks after conversion was 
significantly increased to 61.21 ± 11.51 mL/min/1.73 m2. CCr 
improvement was only revealed in patients who were exposed 
to CNI less than 1 yr (Fig. 3). Proteinuria increased at each mea-
suring point, and it was significantly higher than at the precon-
version period. The mean microprotein in the 24-hr urine col-
lection was 101.8 ± 51.5 mg/day (range: 12.0-221.0 mg/day) at 
the screening, and it gradually increased to 306.1 ± 336.8 mg/
day (range: 10.4-1,270.2 mg/day). Five patients (11.1%) exhibit-
ed proteinuria over 300 mg/day 4 weeks after conversion. Twelve 
patients (26.7%) exhibited proteinuria over 300 mg/day 52 weeks 
after conversion, and 3 of these patients had severe proteinuria 
over 1 g/day. 
Adverse events
A total of 158 adverse events (AEs) were reported during the 
study period. The mean time of AEs was 3.5 ± 1.9 times per per-
son. Severe adverse events that required hospitalization occurr-
ed in 13 cases (8.2%). The most common AE was infection (39.6%) 
followed by digestive symptoms (18.2%) and metabolic events 
(15.1%), such as hyperlipidemia. The 63 events of infection in-
cluded 49 (77.7%) upper respiratory infections, two (3.2%) uri-
nary tract infections, two (3.2%) soft tissue infections, six (9.5%) 
viral infections, such as herpes zoster and herpes simplex, two 
(3.2%) fungal infections, and two (3.2%) pulmonary infections. 
Other AEs included skin rash, itching, oral ulcer, leg edema, my-
algia, diabetes, anemia, androgenic alopecia, acute pancreati-
tis, heart failure, and arrhythmia. One case of acute rejection 
occurred during the study period, and this patient was rescued 
by steroid-pulse therapy. Serum total cholesterol, triglyceride 
and HDL cholesterol were measured on each visit (preconver-
sion, 2, 4, 8, 12, 20, 28, 36, 44, and 52 weeks after conversion). 
Fig. 4 illustrates the trend of serum lipid profile changes during 
the study period. Total cholesterol levels rapidly increased from 
189.2 ± 45.3 mg/dL to 229.2 ± 70.7 mg/dL in the 4 weeks after 
SRL conversion. Triglyceride and high-density lipoprotein lev-
els also increased after SRL conversion. Thirty-one patients be-
gan antihypercholesterol drug (statin analogues) 122.5 ± 78.5 
days after SRL conversion. Only five patients remained statin-
free 52 weeks after conversion. Serum cholesterol and triglycer-
ide levels were controlled with the medication, and their mean 
levels were 193.2 ± 35.6 mg/dL and 171.0 ± 94.2 mg/dL, respec-
tively, at 52 weeks. 
Histological changes
The histological changes are summarized in Table 2. Both pre- 
and postconversion biopsy samples were adequate for evalua-
tion according to Banff 97 criteria (18). The proportions of glob-
al and segmental sclerosis increased from 7.6% ± 13.0% (range: 
0%-57.0%) to 12.7% ± 19.0% (range: 0%-72.0%; P = 0.023) and 
0.9% ± 4.8% (range: 0%-28.6%) to 2.1% ± 6.2% (range: 0%-33.3%; 
P = 0.026), respectively, after SRL conversion. No significant dif-
ferences in mean Banff scores were observed, except for the “ct” 
(tubular atrophy) score, which significantly increased 1 yr after 
conversion (P = 0.012). An increase in the “ct” score was observ-
ed in the patients who were exposed to CNI for less than 3 yr. 
 No significant differences in modified “ah” scores between pre- 
and postconversion were observed in 1-yr biopsies (Fig. 5). Six-
teen of the 37 patients who completed the current study (43.2%) 
exhibited no changes in histological CNI toxicity scores. An im-
proved status in CNI toxicity, which was presented as a lower 
grade at postconversion biopsy than preconversion biopsy, was 
demonstrated in 10 patients (27.0%), but a worsened status was 
Fig. 3. Creatinine clearance before and after SRL conversion according to the CNI 
exposure period. *P value compared to preconversion creatinine clearance.
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observed in 11 patients (29.8%). No significant differences in 
CNI toxicity between the three preconversion biopsy groups 
(early conversion within 1 yr after transplantation, intermediate 
conversion (1-3 yr after transplantation), and late conversion 
over 3 yr after transplantation were observed (Fig. 5B). 
DISCUSSION
Early conversion is a better option than late conversion to avoid 
CNI toxicity or long-term graft survival (7, 8, 21). In a large mul-
ticenter study, the elimination of cyclosporine A (CsA) after 3 
months from a protocol that contained SRL and CsA improved 
renal function, renal histology and graft survival (22, 23). How-
ever, no evidence of a time limit for the conversion of CNI to SRL 
or the irreversible renal change has been reported. In the cur-
rent study, we extended the SRL conversion time to between 6 
months and 5 yr after transplantation and included a protocol 
biopsy prior to and after SRL conversion.
 Our study clearly demonstrated that SRL conversion improv-
ed renal function, but this effect was only observed in the pa-
tients who were exposed to CNI for less than 1 yr after transplan-
tation. Moreover, this effect was not associated with histological 
improvements. These findings suggest a dissociation of func-
tion and histological improvement after SRL conversion, and 
histological improvement after SRL conversion cannot be ex-
pected one year after transplantation in patients with mild to 
moderate graft dysfunction.
 The current study demonstrated improvements in renal func-
tion after SRL conversion, but no significant changes in histo-
logical findings were observed, especially in CNI toxicity. Al-
though some patient demonstrated improved modified “ah” 
scores at 1 yr postconversion, other patients exhibited aggravat-
Table 2. Histological changes in pre- and postconversion biopsies according to the duration of CNI exposure
Histological findings
Duration of CNI exposure
6 month-1 yr (n = 10) 1-3 yr (n = 16) 3-5 yr (n = 11)
Pre-conversion Post-conversion P value Pre-conversion Post-conversion P value Pre-conversion Post-conversion P value
No. of Glomeruli 12.2 ± 6.3 5.5 ± 3.8 0.021 14.6 ± 10.5 9.8 ± 4.9 0.066 11.2 ± 6.1 9.8 ± 5.3 0.619
% of GS 0.5 ± 1.5 4.0 ± 12.6 0.410 10.8 ± 16.8 19.3 ± 23.6 0.071 8.8 ± 11.4 11.6 ± 14.2 0.311
% of SS 0.0 ± 0.0 0.0 ± 0.0 - 0.2 ± 0.9 1.3 ±  2.8 0.147 2.9 ± 9.0 5.4 ± 10.7 0.100
g 0.0 ± 0.0 0.0 ± 0.0 - 0.1 ± 0.3 0.1 ± 0.5 0.669 0.1 ± 0.3 0.1 ± 0.3 -
t 0.4 ± 0.7 0.9 ± 1.1 0.273 0.8 ± 0.8 0.5 ± 0.9 0.136 0.5 ± 0.7 0.2 ± 0.4 0.082
i 0.7 ± 0.5 0.9 ± 1.0 0.591 0.9 ± 0.6 1.2 ± 1.0 0.136 0.9 ± 0.8 0.6 ± 0.5 0.277
v 0.0 ± 0.0 0.0 ± 0.0 - 0.0 ± 0.0 0.0 ± 0.0 - 0.0 ± 0.0 0.0 ± 0.0 -
cg 0.0 ± 0.0 0.0 ± 0.0 - 0.0 ± 0.0 0.0 ± 0.0 - 0.0 ± 0.0 0.1 ± 0.3 0.341
ct 0.2 ± 0.4 0.8 ± 0.6 0.005 0.7 ± 0.6 1.2 ± 0.9 0.006 0.7 ± 0.6 0.5 ± 0.5 0.506
ci 0.3 ± 0.5 0.5 ± 0.7 0.443 0.5 ± 0.5 0.9 ± 1.0 0.138 0.6 ± 0.7 0.5 ± 0.5 0.756
cv 0.2 ± 0.5 0.1 ± 0.3 0.193 0.3 ± 0.6 0.3 ± 0.8 0.817 0.1 ± 0.3 0.3 ± 0.6 0.441
ah 1.0 ± 1.0 1.1 ± 1.0 0.678 0.9 ± 0.8 0.9 ± 0.8 0.751 1.5 ± 0.8 1.5 ± 0.7 > 0.999
mm 0.3 ± 0.5 0.2 ± 0.6 0.591 0.1 ± 0.3 0.1 ± 0.3 > 0.999 0.4 ± 0.7 0.2 ± 0.4 0.506
CNI, calcineurin inhibitor; GS, global sclerosis; SS, segmental sclerosis.
Fig. 5. Calcineurin inhibitor (CNI) toxicity in the biopsy. (A) Change of modified “ah” score. (B) Proportion of modified “ah” score according to exposure duration to CNI; precon-
version versus postconversion 1 yr.
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ed modified “ah” scores. Other scoring systems to evaluate CNI 
toxicity have replaced or modified the Banff score (20, 24). Kam-
bham et al. (24) suggested a formula for CNI toxicity scoring us-
ing multiple histological parameters, such as glomerular scle-
rosis, tubular atrophy, arterial hyalinization, and tubular vacu-
olization. Our analysis of CNI toxicity using the scoring system 
suggested by Kambham et al. revealed post-conversion scores 
that were higher than preconversion scores (data not shown). 
However, the duration of CNI treatment was long enough to 
develop moderate to severe arteriolar changes, and the follow-
up biopsies might have been performed too early for vessels to 
remodel their shapes. These results suggest that earlier conver-
sion studies are required to prove the reversibility of SRL con-
version.
 No mechanisms of SRL conversion for the improvement of 
renal function have been revealed. Intrarenal hemodynamic 
change is one clue of this improvement. CNI use following kid-
ney transplantation is associated with the development of va-
somotor nephrotoxicity (25). The early phase of this toxicity is 
reversible by a reduction in CNI dosage. However, the continu-
ous administration of CNI is associated with chronic vascular 
and tubulointerstitial lesions, which can cause irreversible ne-
phropathy (26, 27). Therefore, the beneficial effect of early CNI 
withdrawal and SRL conversion is at least partially due to a de-
crease in intrarenal vascular resistance parameters (28). A func-
tional improvement in SRL conversion patients who were ex-
posed to CNI less than 1 yr was observed, but no histological 
improvement was observed. SRL can alter reversible intrarenal 
hemodynamicity in the early period, but it cannot reverse CNI-
induced arteriopathy. A similar result was reported in another 
conversion study (29). The authors reported that the functional 
improvement in glomerular filtration rate in the conversion 
group was not associated with less interstitial fibrosis in proto-
col biopsies one year after transplantation. These results sug-
gest that early conversion cannot prevent the progression of 
pathological damage. 
 Unfortunately, proteinuria is a well-known disadvantage of 
SRL conversion (30-32). The current study also demonstrated a 
rapid increase of proteinuria with SRL use. Proteinuria is the 
major concern of SRL conversion from CNI treatment. Protein-
uria related to SRL is a controversial issue. Proteinuria after con-
version from calcineurin inhibitors to SRL has been reported in 
several studies (30-32), but SRL may not be a direct factor for 
proteinuria (33). Proteinuria after SRL conversion could be re-
lated to the previous use of CsA but not SRL, but early SRL use 
with CsA elimination does not induce progressive proteinuria 
(33, 34). The current study demonstrated a rapid increase in 
proteinuria after SRL conversion. An SRL conversion study in 
chronic allograft dysfunction reported that intraglomerular pres-
sure tended to increase, and renal functional reserve decreased 
significantly after SRL conversion form CNI, which was charac-
teristic of hyperfiltration (35). This result may partially explain 
the increase in proteinuria after SRL use. Recently, Stallone et 
al. suggested that SRL-induced proteinuria may be a dose-de-
pendent effect of the drug on key podocyte structures (36). The 
complete inhibition of mTORC1 activity with sirolimus treat-
ment may worsen podocyte function and fail to yield a better 
clinical outcome because the PI3K-mTORC1 function in podo-
cytes is essential for the maintenance of podocyte function and 
the integrity of the filtration barrier (37). Additionally, rapamy-
cin treatment causes atrophy of the renal medulla in mice. The 
levels of rapamycin-sensitive phosphorylated S6 are higher in 
the tubular region under normal conditions, which suggests 
that renal tubular epithelial cells require relatively high mTORC1 
activity for a constant turn-over and that tubular dysfunction or 
atrophy by prolonged mTORC1 inhibition may cause tubular 
proteinuria. Our data also demonstrated a significant increase 
in “ct” score after SRL conversion, and this increase in tubular 
atrophy may contribute to SRL-induced proteinuria. 
 Hyperlipidemia, oral ulcer, edema, anemia, and pneumoni-
tis are related to SRL. Hyperlipidemia significantly affects long-
term graft function (38). Hyperlipidemia is also closely related 
with SRL. However, SRL-induced hyperlipidemia generally re-
sponds to statin analogues (39). Thirty-one patients began statin 
analogues, and hyperlipidemia was well-controlled in the cur-
rent study. A beneficial effect of SRL conversion on renal func-
tion as measured by serum creatinine and creatinine clearance 
was observed, especially in the patients who were converted to 
SRL within 1 yr after transplantation. 
 SRL conversion treatment can be safely applied to patients 
with mild to moderate renal insufficiency. However, SRL con-
version should be considered within 1 yr after transplantation 
because the increased exposure to CNI negatively impacts his-
tological features that may not be reversible, and it may be more 
difficult to improve CCr. 
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